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A b s t r a c t
Since the earliest descriptions of the disease, senile plaques (SP) and neurofibrillary tangles (NFT) have been regarded 
as the pathological ‘hallmarks’ of Alzheimer’s disease (AD). Whether or not SP and NFT are sufficient cause to explain 
the neurodegeneration of AD is controversial. The major molecular constituents of these lesions, viz., ß-amyloid (Aß) 
and tau, have played a defining role both in the diagnosis of the disease and in studies of pathogenesis. The molecular 
biology of SP and NFT, however, is complex with many chemical constituents. An individual constituent could be the 
residue of a pathogenic gene mutation, result from cellular degeneration, or reflect the acquisition of new proteins 
by diffusion and molecular binding. This review proposes that the molecular composition of SP and NFT is largely 
a consequence of cell degeneration and the later acquisition of proteins. Such a conclusion has implications both for 
the diagnosis of AD and in studies of disease pathogenesis.
Key words: Alzheimer’s disease (AD), senile plaque (SP), neurofibrillary tangle (NFT), ß-amyloid (Aß), molecular 
composition, gene mutation, disease pathogenesis.
Communicating author:
Dr R.A. Armstrong Vision Sciences, Aston University, Birmingham B4 7ET, UK. Phone number: 0121 204 41 02, Fax number: 0121 204 40 48, 
Email: R.A.Armstrong@aston.ac.uk
Introduction
Ever since the first descriptions of pre-senile de-
mentia by Alois Alzheimer in 1907 [3], the formation 
of senile plaques (SP) and neurofibrillary tangles 
(NFT) have been regarded as the defining pathologi-
cal features of Alzheimer’s disease (AD). The Khacha-
turian [56] and ‘Consortium to Establish a Registry of 
Alzheimer’s Disease’ (CERAD) [68] criteria emphasi-
se the importance of SP in diagnosis, while the NIA-
Reagan Institute criteria [54] suggest both SP and 
NFT should be considered. Whether SP and NFT are 
sufficient to cause the neurodegeneration of AD, ho-
wever, is controversial and has been questioned by 
a number of authors [8,22,61].
Studies of the molecular biology of SP and NFT 
have played an important role in the development of 
hypotheses as to the pathogenesis of AD. For exam-
ple, the discovery of β-amyloid (Aβ) as the most im-
portant molecular constituent of the SP [44] led ul-
timately to the ‘Amyloid Cascade Hypothesis’ (ACH), 
one of the most influential models of the molecular 
pathology of AD [50]. The ACH proposes that the de-
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precursor protein (APP) [28,45] and presenilin (PSE-
N1/2) genes [63,85], via the generation of pathologi-
cal Aβ peptides, have been linked to familial forms 
of AD (FAD). Hence, the presence of Aβ within SP is 
regarded as the residue of the effect of a pathogenic 
gene mutation that via the accumulation of toxic and 
insoluble Aβ peptides leads to cell death. Since the 
pathological phenotype of familial AD (FAD) is simi-
lar, apart from age of onset, to that of sporadic AD 
(SAD) [13,51,75], studies of gene mutation have had 
a profound influence on the development of theories 
as to the pathogenesis of AD in general [92].
Chemical analysis of SP and NFT in AD reveals 
them to have a complex and varied composition. 
There may be at least three types of factor that co-
uld influence the molecular biology of SP and NFT 
(Fig. 1) [17]. First, a molecular constituent could be 
the residue of a pathogenic gene mutation and the-
refore be directly related to the primary aetiology. Se-
cond, it could be the product of cellular degeneration 
and therefore, a consequence of the disease process 
[14]. Third, SP and NFT could acquire new molecular 
constituents as a result of diffusion and molecular 
binding to existing proteins [10,15,16]. This review 
examines the importance of these three factors in 
determining the molecular composition of SP and 
NFT in AD and discusses the implications in terms of 
diagnosis and pathogenesis.
The molecular composition of SP and NFT
Senile plaques
SP exist in various morphological forms including 
diffuse (‘pre-amyloid’), primitive (‘neuritic’), classic 
(‘dense-cored’), and compact-type (‘burnt-out’) pla-
ques [6,31]. A variety of Aβ peptides are present wi-
thin these plaques and are formed as a result of se-
cretase cleavage of the transmembrane glycoprotein 
APP (Table I) [47]. The most common of these pepti-
des is Aβ42/43 found largely in SP, whereas the more 
soluble Aβ40 is also found in association with blood 
vessels [67,82] and may develop later in the disease 
[30]. Diffuse plaques contain Aβ42/43 as well as APP 
fragments lacking the C-terminus while more matu-
re classic plaques contain Aβ40 in addition to Aβ42/43. 
Moreover, SP have a variety of ‘secondary’ constitu-
ents [11] including silicon and aluminium [65], acu-
te-phase proteins such as α-antichymotrypsin and 
α2-macroglobulin [38,64,99] and their mediator in-
Fig. 1. Factors that influence the molecular com-
position of senile plaques (SP) and neurofibrilla-
ry tangles (NFT) in Alzheimer’s disease (AD).
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Table I. Molecular composition of senile plaques 
(SP) and neurofibrillary tangles (NFT) in Alzheime-
r’s disease.
Lesion Molecular composition
Diffuse SP
APP (lacking C terminus), Aβ oligomers 
especially Aβ42/43, apolipoprotein E, α1-
antichymotrypsin, HSPG, complement pro-
teins (C1q, C3, C4), amyloid-P, may contain 
neuronal and astrocytic markers
Primitive SP
APP (N & C-terminal), Aβ42/43, free ubiqu-
itin, conjugated ubiquitin, PHF-antigen, 
phosphorylated tau, chromogranin-A, bFGF, 
apolipoprotein E, interleukin-6, actylcholi-
nesterase, cholinergic, somatostatin, GABA, 
neuropeptide-Y, parvalbumin, and catecho-
lamine immunoreactive neurites
Classic SP
Aβ42/43 (‘core’), α-synuclein (‘ring’), Aβ40, 
actin, tubulin, phosphorylated tau, 
NF-protein, CAM, chromogranin-A (‘ring’), 
α2-macroglobulin, complement proteins 
(‘core’), immunoglobulins (‘core’), amyloid-P, 
α1-antichymotrypsin, antitrypsin, antith-
rombin III, apolipoprotein E and D (‘core’), 
DOPPEL, bFGF, PrP, may contain actylcholi-
nesterase, cholinergic, somatostatin, GABA, 
neuropeptide-Y, parvalbumin, and catecho-
lamine+ neurites (‘ring’), silicon/aluminium 
(‘core’), interleukin-6 (‘ring’)
Intracellular 
NFT
phosphorylated 3R/4R tau (C & N terminal), 
ubiquitin (C & N termini), MAP, NF-protein, 
apolipoprotein E, synaptophysin, bFGF, 
HSPG
Extracellular 
NFT
degraded tau (lacking N/C termini), GFAP, 
Aβ, ubiquitin (lacking N-terminus), amylo-
id-P, Apo E
Aß – ß-amyloid, APP – amyloid precursor protein, bFGF – basic fibroblast 
growth factor, CAM – cell adhesion molecule, GFAP – glial fibrillary acidic 
protein, HSPG – heparan suphate proteoglycan, MAP – microtubule asso-
ciated proteins, NF-protein – neurofilament protein, PHF – paired helical 
filament, PrP – prion protein.
position of Aβ is the initial pathological event in the 
disease leading to the formation of NFT, cell death, 
and ultimately dementia. Mutations of the amyloid 
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terleukin-6 [84], intercellular adhesion molecules 
such as cell adhesion molecule 1 (CAM1) [38], apo-
lipoprotein E (apo E) which is present in the earliest 
stages of SP formation [105] and D (apo D) [32], the 
heterodimeric glycoprotein clusterin, vibronectin, 
the complement proteins C1q, C4 and C3 [100], blood 
proteins such as amyloid-P (especially in classic SP), 
cathepsins B/D [86], and the sulphated glycosami-
noglycans such as heparan sulphate proteoglycan 
(HSPG). In addition, the prion like protein DOPPEL 
encoded by the PRND gene may occur in peripheral 
regions of SP [39]. 
Neurofibrillary tangles
The microtubule associated protein (MAP) tau is 
the most important constituent of the paired helical 
filaments (PHF) and straight filaments which compri-
se cellular NFT in AD. There is a single gene for tau and 
different isoforms result from alternative splicing and 
post-transcriptional changes [37]. AD is therefore con-
sidered to be a tauopathy, a group of disorders that 
also includes Pick’s disease (PiD), corticobasal dege-
neration (CBD), the NFT predominant form of senile 
dementia (NFT-SD), argyrophilic grain disease (AGD), 
progressive supranuclear palsy (PSP), and parkinsoni-
sm-dementia complex of Guam (Guam PDC) [26,34]. 
The composition of tau differs between the different 
tauopathies. For example, PiD is characterised by tau 
with three microtubule repeats (3R tau) while PSP and 
CBD are composed of four repeat (4R) tau [33,70]. In 
AD both 3R and 4R tau are present, the 3R/4R tau ratio 
being highly variable but specific to individual types 
of neuron [96]. In addition, the molecular composition 
of the NFT varies markedly depending on whether 
they are intracellular NFT (I-NFT) or extracellular NFT 
(E-NFT). Hence, unlike I-NFT, E-NFT are glial fibrillary 
acidic protein (GFAP) and Aβ immunoreactive [104], 
and also contain significant amounts of amyloid-P 
[77] and ubiquitin [21]. 
The effect of pathogenic gene mutations
The first demonstration of a direct association be-
tween a pathological protein and a gene mutation in 
neurodegenerative disease was made in AD [28,45]. 
A primary pathogenic role for the APP gene was sug-
gested by the discovery of missense mutations in a 
small number of families, mutations in exons 16 and 
17 being the first established genetic link with FAD 
[46]. There are three isoforms of APP, viz., APP695, 
APP751, and APP770, all of which are cell surface gly-
coproteins with a single membrane-spanning region 
[25]. Aberrant degradation of APP is believed to re-
sult in Aβ formation, especially the peptide Aβ42/43, 
the major constituent of the SP. APP has a large 
extracellular N-terminal domain and a short intracel-
lular C-terminal domain while the Aβ sequence itself 
has 15 amino acids lying within the membrane and 
28 extracellular amino acids. The metabolism of APP 
is mediated by α-, β-, and γ-secretase and in cultured 
cells that overexpress APP, there are two catabolic 
pathways. First, the ‘non-amyloid’ pathway in which 
APP is cleaved within the Aβ sequence by α-secretase 
and second, the ‘amyloid’ pathway in which APP is 
cleaved by β- and γ-secretase after endocytosis of 
the trans-membrane portion [76]. It was originally 
believed that soluble Aβ was non-toxic but became 
extremely toxic once fibrils were formed [76]. More 
recent evidence suggests that Aβ oligomer interme-
diates are more likely to be the dominant toxic spe-
cies [57]. Hence, altered proteolytic processing of APP 
and the accumulation of excess Aβ is assumed to be 
an early pathological event in FAD, a process which 
also occurs to a limited extent in aged humans [79]. 
Following Aβ deposition, the formation of SP, micro-
glial activation, astrocytosis, and neuritic dystrophy 
presumably lead to the formation of NFT, cell death, 
and dementia as proposed by the ACH [50]. 
Subsequently, the most common subtypes of 
FAD were linked to mutations of the PSEN [63,85] ge-
nes and the effect of these mutations was also assu-
med to lead, albeit more indirectly, to the enhanced 
deposition of amyloidogenic species of Aβ [47]. The 
normal function of the PSEN genes, and how gene 
mutations result in Aβ deposition in these cases is 
unclear. PSEN1 may be involved in notch signalling 
[88] and may therefore be important in cell differen-
tiation. PSEN1/2 genes may also be implicated via the 
perturbation of cellular calcium homeostasis [106] 
or in interactions with the transcriptional coactiva-
tor cAMP-response element binding (CREB-binding) 
protein which plays a key role in regulating gene 
expression [41]. In addition, PSEN genes are part of 
the γ-secretase complex which are important in ge-
nerating Aβ from APP. Hence, mutant PSEN1 could 
enhance 42-specific-γ-secretase cleavage of normal 
APP resulting in increased deposition of Aβ42/43 [93].
Hence, there is a close relationship between spe-
cific gene mutations, amyloid deposition, and FAD. 
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rat, injury to an area of brain results four to seven 
days later in the presence of APP in axonal swellings, 
cell bodies, and dystrophic neurites [89]. Lesions of 
the fimbria-fornix pathway in the rat also result in a 
marked accumulation of APP in regions of the hip-
pocampus associated with degenerating choliner-
gic fibres [23,35]. Injections of toxins into the brain 
produce very similar results, e.g., there are changes 
in the expression or induction of APP in brain cells 
after intrathecal or intraparenchymal injections of 
various toxins [20] while administration of chloro-
quine results in the production and accumulation of 
C-terminal fragments of APP in the cell bodies of py-
ramidal cells [19]. Furthermore, APP shares structural 
features with precursors of epidermal growth factor 
suggesting that APP is an endogenous protectant 
activated by injury to brain cells [81]. These observa-
tions have suggested alternative schemes of patho-
genesis in which Aβ is not the primary cause of AD. 
Hence, theories involving perturbations of vesicular 
trafficking, the cytoskeletal network, and the distri-
bution of membrane cholesterol are increasingly be-
ing explored [35].
Many other constituents of SP may be a consequ-
ence of structural degeneration of the cell. Approxi-
mately 40% of diffuse plaques contain degenerating 
neuronal perikarya [5,7,69] and many contain the 
processes of astrocytes. Acetylcholinesterase rich 
neurites have been found in SP and may be the de-
generating axonal terminals of neurons originating 
in the nBM [91]. Cholinergic neurites, and neuri-
tes positive for somatostatin, γ-amino butyric acid 
(GABA), neuropeptide Y [59], and the catecholamines 
have all been recorded in SP [91]. As a consequence 
of neuritic degeneration, PHF antigens, tau, A68 pro-
tein, ubiquitin, and NF epitopes are also present [83]. 
In addition, the presence of neuronal markers such 
as parvalbumin suggests the preferential incorpora-
tion of processes of pyramidal neurons into SP [1]. 
The presence of chromogranin A, a soluble protein 
in dense-core synaptic vesicles within the dystrophic 
neurites of the ‘coronas’ of classic plaques, may also 
be the result of cellular degeneration [72,80]. 
Neurofibrillary tangles
The formation of NFT could be a part of the neu-
rons limited response to injury [103] as neurons will 
often respond to degeneration by increasing the syn-
thesis of tau [43]. Dopamine denervation and sep-
In the case of APP, the product Aβ can be directly 
related to the gene. In other FAD cases, e.g., those 
linked to PSEN genes, the connection between the 
gene mutation and the accumulation of Aβ may be 
more indirect. These processes, however, account for 
only a small proportion of cases of AD; the APP and 
PSEN1/2 genes together accounting for less than 5% 
of cases [52]. In addition, various questions remain, 
e.g., if the ACH is correct, how does Aβ lead to the 
formation of tau [8], how do Aβ and tau cause cell 
death in AD, why is the density of lesions so low in 
some AD cases, and why is the pathology of FAD and 
SAD so similar?
The effect of structural degeneration 
within the cell
How do gene mutations result in 
pathology?
That a more complex relationship may exist be-
tween APP mutation, Aβ and AD was first proposed 
in 1993 [71]. Amino acid changes associated with the 
codon 717 mutation of the APP gene (APP
717
) appe-
ared to shed little light on the pathogenic mecha-
nism of AD and existing data from neurotoxicity 
experiments did not establish a primary role for Aβ 
in disease pathogenesis [71]. In addition, deposition 
of Aβ occurs only in areas of cortex with viable neu-
rons, i.e., functional neurons were necessary for the 
presence of Aβ [65]. Hence, Aβ may not necessari-
ly kill neurons but may be secreted in response to 
cellular damage. Furthermore, generation of the pa-
thological Aβ sequence requires cleavage by β- and 
γ-secretase at the N and C-terminal sites [66,103]. As 
the C-terminal domain lies within the membrane, 
membrane damage resulting from cellular break-
down, might therefore be a prerequisite for the Aβ 
fragment to be generated [17]. 
Senile plaques
Animal models suggest that Aβ peptides may be 
formed in response to cellular degeneration. Lesions 
of the nucleus basalis of Meynert (nBM) in the rat, 
for example, elevate APP synthesis in cortical neu-
rons [101]; the production of excess APP being a re-
sponse to loss of functional innervation. Similarly, 
subacute and prolonged neuronal damage in hu-
mans can induce the formation of APP [20]. In the 
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tal lesions affecting cholinergic and GABA neurons 
projecting to the dentate gyrus result in the loss of 
dendritic MAP2 and tau immunostaining [97]. Hence, 
transynaptic changes affecting dentate gyrus neu-
rons may result in the precursor stages of NFT. NFT 
may also contain additional constituents that result 
from cellular degeneration [12] such as NF proteins 
and synaptophysin [4]. 
The effect of secondary acquisition of 
proteins
Proteins already present within SP and NFT may 
bind additional molecular constituents, e.g., PHF 
and amyloid fibres can ‘decorate’ themselves with 
various proteins [10,102]. In addition, Aβ has a num-
ber of trophic properties and can bind metals such 
as copper, iron, and zinc [18]. Furthermore, during 
aging, long-lived proteins accumulate post-transla-
tional modifications (‘Maillard reaction products’) 
such as cross-linking, decreased solubility, and incre-
ased protease resistance [87]. These changes may 
alter the chemical composition of a lesion with time 
and significantly change its binding properties [95]. 
Electrostatic interactions may also be important in 
binding exogenous components to Aβ [42].
Senile plaques
Apo E labels a proportion of SP [98] and is usually 
detected after the appearance of Aβ [62] suggesting 
that it is not a prerequisite for plaque formation even 
in individuals expressing allele ε4 but is acquired se-
condarily. Apo E itself can bind to several proteins 
including Aβ and in the cell targets lipoprotein partic-
les [90]. Several acute-phase proteins and proteins 
associated with the immune system accumulate in 
SP. Interleukin-6 is enhanced in both mild and mode-
rate AD, is a mediator of acute-phase proteins, and 
may be responsible for their accumulation within 
SP [84]. The membrane attack complex (MAC) has 
been identified in the dystrophic neurites of SP [60], 
and whereas immunoglobulin G (ImG) has not been 
identified, SP are associated with a variety of com-
plement proteins, CAM, and proteins that may have 
originated in the blood plasma [11,38]. The presence 
of C
3 and antichymotrypsin suggest that the classic 
pathway is activated in association with diffuse pla-
ques but it is unclear whether the process proceeds 
beyond C
3. C3 is abundant in serum and therefore, 
could originate in blood but is also produced by ma-
crophages and astrocytes [48]. Amyloid-P is a com-
plex glycoprotein made in the liver and present in 
blood serum [2] and is found in both SP and NFT sug-
gesting that the substance accumulates following 
impairment of the blood brain barrier [9,36,55]. Ap-
proximately 90% of Aβ positive SP contain amyloid-P 
[58]. The staining pattern of amyloid-P parallels that 
of the complement proteins suggesting that it may 
assist microglia during phagocytosis [2].
SP also contain basic fibroblast growth factor 
(bFGF), a substance that appears to attract neurites 
into the plaque [29]. As a consequence, SP acquire 
various markers associated with the processes of 
neurons and glial cells. In addition, prion protein 
(PrP) may accumulate at the periphery of Aβ positive 
plaques [49]. 
Neurofibrillary tangles
The maturation of NFT is associated with seve-
ral changes in their molecular biology. Hence, E-NFT 
contain many SP constituents including Aβ, HSPG, 
amyloid-P, and various serpins [77,78]. I-NFTs are 
less compact, silver positive, and eosinophilic com-
pared with E-NFT [106]. E-NFTs are also immunoreac-
tive for GFAP and Aβ, both of which are likely to be 
deposited after cell death. The acquisition of Aβ by 
E-NFT suggests either that Aβ is inaccessible to I-NFT 
or that there are conformation changes of the prote-
ins in the extracellular space that facilitate binding 
of Aβ [95]. A major constituent of NFT is ubiquitin, 
which is found either as a free molecule or as a pro-
tein-ubiquitin conjugate. Ubiquitin may contribute 
to the polymerization of abnormal fibriller structu-
res in an attempt to eliminate them [21]. As I-NFT 
develop into E-NFT, they lose the N/C termini of tau 
and two-thirds of the N-terminus of ubiquitin [95]. 
NFT are also immunopositive for apo E [73]. In AD, all 
apo E positive neurons are positive for PHF proteins 
but not all PHF, tau-2 positive neurons exhibit apo 
E immunoreactivity [24]. These results suggest that 
apo E plays a secondary role in NFT formation and 
is accumulated within neurons in response to repair 
processes induced by NFT. In the presence of calcium 
ions, HSPG will bind to the free carboxyl groups of 
NFT proteins and this binding may play a role in in-
creasing the insolubility of PHF [78]. In addition, bFGF 
binds to heparinase sensitive sites in NFT due to the 
presence of HSPG [78]. The MAC has also been iden-
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tified in association with NFT [53]. Neurons remove 
membrane inserted MAC fragments by endocytosis 
and hence, retrograde transport to cell bodies may 
result in the attachment of MAC to abnormal cyto-
skeletal proteins such as tau [53].
Discussion 
What determines the composition of 
SP and NFT?
The SP and NFT of AD have a rich molecular bio-
logy and a summary of the possible origins of their 
major molecular constituents is shown in Fig 2. The 
only constituent unequivocally related to a gene pro-
duct is Aβ, being directly related to mutations of APP. 
Fig. 2. The proposed origin of the main mole-
cular constituents of senile plaques (SP) and 
neurofibrillary tangles (NFT) in Alzheimer’s di-
sease (AD): Aβ (b-amyloid), ACHE (acetylcho-
linesterase), ACT (α1-antichymotrypsin), Am-P 
(Amyloid-P), APP (amyloid precursor protein), 
Apo E (Apolipoprotein E), bFGF (basic fibroblast 
growth factor), CAM (cell adhesion molecule), 
CHOL (cholinergic), Chrom-A (chromogranin-A), 
GABA (γ-amino butyric acid positive neurites), 
GFAP (glial fibrillary acidic protein), HSPG (he-
paran suphate proteoglycan), MAC (membrane 
attack complex), MAP (microtubule associated 
proteins), NF-protein (neurofilament protein), 
PARV (parvalbumin positive neurites), PHF (pa-
ired helical filament), PrP (prion protein), SOMAT 
(somatostatin positive neurites), Ub (ubiquitin), 
Synapt (synaptophysin).
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The degree to which Aβ ‘directly’ promotes cell de-
ath, however, is more controversial. First, FAD cases 
are similar, apart from age at onset, to SAD [51,75] 
and hypotheses such as the ACH do not specify what 
initiates the common late-onset form of AD [94]. 
Second, it is difficult to establish a mechanism that 
directly links a specific APP mutation to cell death. 
A variety of mechanisms have been proposed by 
which abnormal and misfolded proteins may affect 
cellular homeostasis including disruption of the ubi-
quitin degradation system, axonal transport, synap-
tic function, and protein sequestration and these are 
reviewed in detail by Forman et al. [40]. Third, the 
presence of Aβ within SP may obscure the primary 
aetiology because of secondary toxicity effects. Fo-
urth, many of the molecular constituents of SP and 
NFT may be formed as a response to cellular degene-
ration including Aβ and tau [14,74,81,101].
SP and NFT also contain several constituents that 
are directly related to cellular degeneration (Fig. 2). 
Hence, synaptic disconnection, neuritic degenera-
tion, and invasion by glia add various constituents 
to developing SP. These processes may explain the 
presence of tau, PHF antigens, synaptic proteins, and 
specific neurotransmitter-positive neurites within SP. 
Subsequently, as lesions age, the activity of some 
constituents is lost and new compounds acquired. 
Many of these newly acquired proteins may be made 
by glial cells or be derived from the bloodstream as 
a result of breakdown of the blood brain barrier. 
Hence, GFAP, complement proteins, and acute pha-
se proteins become incorporated into SP. Acquisition 
of substances by SP as a result of surface diffusion 
and molecular binding may cause further changes 
in plaque morphology and alter the properties of 
the plaque so that it can bind yet further proteins 
[10,15,16]. 
Implications for diagnosis 
Aβ and tau are currently the most important 
molecular markers of AD and the various diagno-
stic criteria emphasise the presence of either SP 
alone or both SP and NFT in pathological diagnosis 
[66,68,103]. Nevertheless, the molecular complexity 
of SP and NFT and the possible origins of the various 
constituents raise questions about the reliability of 
using any constituent as the sole pathological marker 
of disease. First, when many chemical constituents 
are present, there is the problem of distinguishing 
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the primary ‘pathological’ proteins from reactive pro-
ducts, the breakdown products of the cell, and the 
compounds acquired by surface diffusion. Studies of 
FAD have had the most significant influence in iden-
tifying the ‘primary’ pathogenic protein, viz., Aβ, the 
results then being extrapolated to SAD. Aβ, however, 
may itself be a reaction to cellular degeneration ra-
ther than being its cause [14]. Second, the chemical 
composition of SP and NFT changes as the lesions 
mature and, in some cases, activity of the primary 
molecular constituents may be reduced or become 
substantially altered, and this may cause problems 
in the diagnosis of AD especially of longer duration 
cases. Nevertheless, if the value of SP and NFT in the 
diagnosis of AD is questioned, there is the problem 
of how AD is to be defined [17].
Implications for disease pathogenesis
In the conventional view of AD pathogenesis as 
illustrated by the ACH (Fig. 3A), a causal pathway 
is hypothesised linking mutations of APP to cell in-
jury and death; the latter mediated presumably by 
a variety of changes in cellular homeostasis [40] and 
caused by the accumulation of Aβ peptides [50]. This 
review, however, proposes a more complex interrela-
tionship between these elements (Fig. 3B) in which 
the primary factor is the age-dependent breakdown 
of anatomical systems and pathways within the bra-
in and the consequence loss of synapses [27]. The 
extent of this aging effect, which begins early in life, 
is mediated by the degree of lifetime stress (the ‘al-
lostatic load’). The brain is the ultimate mediator of 
stress-related mortality through hormonal changes 
resulting in hypertension, glucose intolerance, car-
diovascular disease, and immunological problems 
[27]. The consequence is gradual synaptic disconnec-
tion, neuronal degeneration, and the upregulation of 
genes determining various reactive and breakdown 
products [14,74,81,101]. Second, in small numbers of 
families, specific APP or PSEN mutations influence 
the outcome of this age-related degeneration by de-
termining the solubility and/or toxicity of the mole-
cular product. Cells have mechanisms to protect aga-
inst the accumulation of misfolded and aggregated 
proteins including the ubiquitin system and the pha-
gosome-lysosome system. Neuronal degeneration 
in individuals with specific mutations results in the 
accelerated formation of Aβ and tau, and then a fur-
ther phase of ‘secondary’ neurodegeneration, which 
Fig. 3A-B. Relationships between gene mutation 
and disease phenotype in Alzheimer’s disease 
(AD). A. The amyloid cascade hypothesis (ACH) 
to explain the pathogenesis of familial AD (FAD). 
B. Modified scheme to explain the pathogenesis 
of FAD and sporadic AD (SAD): APP (amyloid pre-
cursor protein), Aβ (β-amyloid), Apo E (Apolipo-
protein E), NFT (neurofibrillary tangle), SP (senile 
plaque), PSEN (presenilin).
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overwhelms the protection systems. Early-onset FAD 
is the consequence of this process. 
By contrast, in individuals without a specific ge-
netic mutation, but where more complex genetic and 
environmental risk factors are present, the outcome 
of age-related loss of synapses is mainly soluble and 
smaller quantities of insoluble proteins which are de-
graded by the cellular protection systems and do not 
significantly accumulate to form SP and NFT. With 
advancing age, however, the protective systems be-
come less effective resulting in slowly accumulating 
quantities of Aβ and tau. The result of these insidio-
us processes is that the cellular protection systems 
do not become overwhelmed until much later in life; 
the consequence being late-onset SAD. The advan-
tage of this modified scheme is that it may explain 
why the phenotypes of FAD and SAD are similar, why 
SP and NFT often appear to be distributed indepen-
dently within the brain, and reflects data suggesting 
that Aβ and tau are formed as a response to cellular 
degeneration.
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